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In mice, clonal tracking of hematopoietic stem cells
(HSCs) has revealed variations in repopulation char-
acteristics. However, it is unclear whether similar
properties apply in primates. Here, we examined
this issue through tracking of thousands of hemato-
poietic stem and progenitor cells (HSPCs) in rhesus
macaques for up to 12 years. Approximately half of
the clones analyzed contributed to long-term repo-
pulation (over 3–10 years), arising in sequential
groups and likely representing self-renewing HSCs.
The remainder contributed primarily for the first
year. The long-lived clones could be further subdi-
vided into functional groups contributing primarily
to myeloid, lymphoid, or both myeloid and lymphoid
lineages. Over time, the 4%–10% of clones with
robust dual lineage contribution predominated in
repopulation. HSPCs expressing a CCR5 shRNA
transgene behaved similarly to controls. Our study
therefore documents HSPC behavior in a clinically
relevant model over a long time frame and provides
a substantial system-level data set that is a reference
point for future work.
INTRODUCTION
Blood is a highly regenerative, multifunctional tissue and a rela-
tively small population of self-renewing hematopoietic stem cells
(HSCs) can regenerate all blood cell types for the lifetime of the
host (Kondo et al., 2003). Transplant of HSCs exploits these
properties for treatment of various human diseases and as ameans to gene-modify hematopoietic cells for genetic therapies
(Kohn and Candotti, 2009; Weissman, 2000). Repopulation
following transplant occurs through the combined engraftment,
growth, and differentiation of a large number of hematopoietic
stem and progenitor cells (HSPCs) including self-renewing
HSCs as well as more differentiated and lineage committed pro-
genitor cells; yet, the individual and cumulative behavior of the
HSPCs at the system level is not well understood. Murinemodels
have provided valuable insights into the regenerative potentials
of HSCs, having the benefit of established assays for purification
of HSCs from among the diverse HSPCs in the bone marrow
(Purton and Scadden, 2007). Historically, HSCs have been pre-
sumed to be biologically homogeneous and possess an unlim-
ited self-renewal potential. More recently, however, single-cell
studies have reported significant cell-to-cell variations in repo-
pulation kinetics, life span, and sensitivity to extracellular stimuli
(Benveniste et al., 2010; Copley et al., 2012; Jordan and
Lemischka, 1990; McKenzie et al., 2006; Morita et al., 2010;
Mu¨ller-Sieburg et al., 2002; Osawa et al., 1996; Pina et al.,
2012; Smith et al., 1991). Interestingly, even the multipotent
behavior of HSCs has recently been shown to vary, with some
HSCs being biased toward either myeloid or lymphoid lineages
(Copley et al., 2012; Lu et al., 2011; Muller-Sieburg et al.,
2012). Unlike the extensive polyclonal repopulation seen in pri-
mates, murine studies demonstrated the behaviors of a single
or a few repopulating clones per mouse (Copley et al., 2012;
Jordan and Lemischka, 1990; Lemischka et al., 1986; Muller-
Sieburg et al., 2012; Smith et al., 1991). Some recent studies
have investigated oligoclonal repopulation (dozens of clones) in
mice (Cornils et al., 2012; Gerrits et al., 2010; Lu et al., 2011;
Naik et al., 2013; Verovskaya et al., 2013); nevertheless, insights
gained by translating these studies into an understanding of
human repopulation are limited because of the far greater
complexity of polyclonal reconstitution as well as the greater de-
mands placed on stem cells within the larger and longer-livedCell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc. 473
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understanding of HSC biology from murine models, the func-
tional properties of primate HSPCs following transplant remain
poorly characterized.
All current transplant protocols for humans and nonhuman
primate models utilize partially purified CD34+ cell populations,
of which only a small proportion represent true HSCs. Because
purification of primate HSCs is not as yet technically feasible,
the primary method utilized to track repopulation in transplant
for humandiseases has been through the use of integrating retro-
viral vectors that ‘‘mark’’ individual HSPCs through differential
semirandom genomic integration sites. In early clinical studies,
the use of gamma-retroviral vectors skewed repopulation due
to insertional mutagenesis that often resulted in malignant trans-
formation (Hacein-Bey-Abina et al., 2010; Nienhuis et al., 2006;
Stein et al., 2010). More recent clinical trials using lentiviral
vectors have tracked repopulation without obvious genotoxic
effects, revealing long-term repopulation by thousands of
gene-engineered cells (Aiuti et al., 2013; Biffi et al., 2013; Cartier
et al., 2009;Cavazzana-Calvo et al., 2010). These studies showed
that the early phase of the hematopoietic reconstitution in
patients (1.5–2 years) was achieved by a large number of low-fre-
quency clones, many of which transiently contributed to the
blood.However, the long-termbehavior patternsof the vast num-
ber of HSPCsworking together to reconstitute the complex poly-
clonal hematopoietic system remain unclear. It is also important
to note that human clinical studies may not be the best setting to
study normal HSPC repopulation because for ethical reasons all
such studies are in the context of a diseased hematopoietic sys-
tem and the introduction of disease-corrective transgenes may
provide favorable repopulation by the gene-corrected HSPCs.
The nonhuman primate autologous HSPC transplant model is
arguably the animal model most closely resembling humans; its
treatment conditions—including the use of CD34+ cells and
mobilization and conditioning regimens—all parallel those of
human (Heim and Dunbar, 2000; Shi et al., 2002). We previously
demonstrated long-term stable hematopoietic reconstitution in
rhesus macaques after transplantation of autologous CD34+
HSPCs transduced with lentiviral vectors (An et al., 2001, 2007;
Sander et al., 2006). These animals maintained stable long-
term marking for as long as 12 years without any genotoxic
effects resulting from transplant. The behaviors of HSPC
clones at the system-level were characterized using a deep-
sequencing-based clonal tracking assay (Kim et al., 2010), which
can quantify a large number of individual clones in parallel
by vector integration site (VIS) sequence enumeration. We
observed that thousands of HSPCs engrafted, and they main-
tained long-term hematopoiesis at a constant level through
sequential expansions of different groups of clones. High-
throughput, long-term clonal tracking in our test animals re-
vealed high variability in HSCs for their lineage outputs, including
myeloid-biased, lymphoid-biased, and balanced subtypes.
RESULTS
Long-Term Stable Marking after CD34+ HSPC
Transplantation
The subjects of this study were four rhesus macaques trans-
planted with autologous CD34+ HSPCs from mobilized periph-474 Cell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc.eral blood (mPB) after a myeloablative dosage of total body
irradiation for periods of 4 to 12 years (An et al., 2001, 2007;
Sander et al., 2006). Long-term repopulation of HSPCs in two
animals (95E132 and 2RC003) was analyzed after transplant
with CD34+ cells marked with lentiviral vectors (human immuno-
deficiency virus [HIV]-based, self-inactivating [SIN-HIV] vectors
expressing EGFP) (An et al., 2001; Sander et al., 2006). As a
model of genetic therapy for HIV-1 disease, two other animals
(RQ3570 and RQ5427) were transplanted with CD34+ HSPCs
engineered with simian immunodeficiency virus (SIV)-based
vectors expressing both EGFP and shRNA against the HIV-1
coreceptor, C-C chemokine receptor type 5 (CCR5) (An et al.,
2007). The potency and safety of the shRNA (sh1005), selected
from hundreds of other candidates, was previously demon-
strated both in vivo and in vitro (Shimizu et al., 2009, 2010).
Animal 2RC003 was cotransplanted with CD34+ HSPCs trans-
duced with SIN-HIV vectors expressing the mutant herpes sim-
plex virus-1 thymidine kinase (HSV1-sr39tk) gene for position
emission tomography (Sander et al., 2006). These HSV1-
sr39tk-expressing cells repopulated at 0.01%–0.2% of total
blood for the first year and were removed by ganciclovir IV treat-
ment at 23months posttransplant. In all animals, the lymphocyte
recovery was slower than that of the granulocytes (grans) or
monocytes. After an initial phase of fluctuation for about
6–12 months, all tested blood lineages showed stable marking
over the long-term (Figure 1). To date, all animals remain healthy,
with no sign of malignant transformation.
Total peripheral blood cells (PBCs) for 95E132 and fraction-
ated grans and peripheral blood mononuclear cells (PBMCs)
for animals 2RC003, RQ5427, and RQ3570 were serially
collected over the entire analysis period so we could study the
longitudinal behavior patterns of repopulating HSPC clones in
these animals (Table 1). Different blood cell types (CD4+,
CD8+, CD14+, CD18+, and CD20+ cells and mPB CD34+
HSPCs) were also isolated near the experiment end point to
study lineage-output potentials of long-term engrafted clones.
All sorted cell samples showed at least 98.7% purity except for
CD4+ cells from RQ5427 and 2RC003 (94.1% purity) (Table S1
available online).
Clonal Tracking Assay
The repopulation of individual HSPCs was tracked by the distin-
guishing VIS of each vector-marked clone. The frequency of
each clone was quantitatively analyzed by large-scale VIS
sequencing and bioinformatics analysis of VIS sequences. We
optimized the assay conditions to enable quantitative VIS
sequencing, including the amount of input DNA, the intensity of
sequencing, data analysis standards to restrict detection biases,
and the conditions for concurrent analysis of the 50 and the 30
vector-host junctions (Kim et al., 2010). Briefly, the genomic
loci and the relative frequencies of individual vector integrants
were determined by a TaqaI-mediated, bidirectional VIS assay
(see Supplemental Experimental Procedures for details). During
the assay, the TaqaI restriction enzyme generated different
lengths of PCR amplicons, each harboring a distinct VIS
sequence (Figure S1 available online). Due to inefficient
sequencing of PCR amplicons of >500 bp with our experimental
conditions, only the vector integrants that generated %500 bp
VIS PCR amplicons at either the left or right vector-host
Figure 1. Longitudinal EGFP Marking in Four Rhesus Macaques
The levels of EGFP expression in granulocytes (grans; green), monocytes
(Monos; brown), lymphocytes (Lymphs; red), red blood cells (RBC; purple),
and platelets (PLT; blue) were assayed by flow cytometry, based on the
forward scatter versus side scatter plot. PLTs were also gated on CD41+ cells.
Data represent longitudinal follow-up for 38–145 months posttransplant, de-
pending on the test animal. Data gathered during the ganciclovir IV treatment
(see arrow at 23 months posttransplant) and within the 2 week period after
leukapheresis have been excluded. See Table S1 for more details.
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were subjected to quantitative analysis. The assay results were
validated by clone-specific real-time PCR of six chosen QVI
clones (Figure S2A).
Long-Term Reconstitution by Thousands of HSPC
Clones with Highly Variable Detection Frequencies
Variable levels of polyclonal repopulation were observed in each
animal. VIS analysis revealed a range of 30 to 1,338 unique
vector integrants, each representing progeny derived from a
single vector-marked HSPC per test sample, totaling 846–
5,758 per animal (Table 1 and Table S2). The total number of
unique vector integrants recovered from each animal was pro-
portional to the number of vector-marked HSPCs that were
infused at the beginning of the experiment (Figure 2A). We previ-
ously estimated that approximately 40.3% of vectors were QVI,
based on a simulation with random vector integration sites (Kim
et al., 2010). In our data sets, 61%–83% of the total recovered
vector integrants were QVIs (Table 1). The discrepancy between
the computational prediction and the assay results may be due
to an assay limitation to detect some vectors remotely located
from the TaqaI restriction sites in the genome. Further biostatis-
tical analysis demonstrating optimization of VIS analysis is in the
Supplemental Information (see Figure S2B). Individual QVIclones in each animal showed highly variable detection fre-
quencies. While thousands of different clones presented, only
a small number of clones dominated the blood repopulation
over time. For example, the 5% most frequent QVI clones
contributed on average 49%–72% of the total QVI repopulation
(up to 60%–88% over time) in each animal with the most preva-
lent clone showing an average relative detection frequency of
0.0322–0.1028 (based on an average across all time points) (Fig-
ure 2B). In contrast, the majority of QVI clones (43%–71%) were
infrequently detected with an average frequency of <0.0002,
contributing to <7% of total QVI repopulation over time in all
animals except RQ3570. In animal RQ3570, the QVI clones
with <0.0002 frequency contributed to <23% of total repopula-
tion. In this animal, the mean and the standard deviation of the
relative frequencies among individual clones were lower than
those of other animals (see Figure 2B), due most likely to a rela-
tively short follow-up time (3 years) and also to the greater pres-
ence of clones (four to seven times as many) in this animal.
Long-Term, Stable Hematopoietic Reconstitution Was
Maintained through Sequential Expansion of Different
HSPC Clones
In test animals, the levels of total vector-marked cells in the
blood were maintained at relatively constant levels for years
following the first 6–12 months posttransplant. To determine
how the large number of HSPC clonesmaintained hematopoietic
homeostasis, we analyzed the patterns of clonal repopulation
over time by clustering QVIs based on their frequency profiles
in serially collected PBCs (in animal 95E132) or grans/PBMCs
(in animals 2RC003, RQ5427, and RQ3570) (Figure 3A). Only
QVIs with an average relative frequency ofR0.0002 (calculated
across all time points) were included for cluster analysis because
they provided reliable signals of clonal behavior over time. These
QVIs were often detected atmore than three time points, thereby
enabling a traceable trajectory of their longitudinal behaviors
(see Figure S2D for details). Low-frequency clones (<0.0002 rela-
tive frequency) were excluded from the analysis because their
signals were expected to be noisier and inconsistently available
across time points due possibly to uneven PCR amplification of
low-frequency clones during the assay process. QVI clones with
an average frequency of R0.0002 were clustered into 5–8
groups, depending on cell types and animals, using the WGCNA
package (Langfelder and Horvath, 2008) (Figure 3A and Fig-
ure S3A). Except for the smallest cluster among the data sets
(cluster-1 with nine clones in the 2RC003 PBMC data set),
all clusters were clearly separable, with a significance level
jZsummary.qualj of >10 (Langfelder and Horvath, 2008). The
repopulation kinetics of clusters-1 to -8 demonstrate sequential
expansions of different clones, peaking at different time points.
Cluster-1 corresponds to the first wave of clones repopulating
at the earliest time point, followed by cluster-2 and continuing
through the final cluster (cluster-5 or -6 for RQ3570 and clus-
ter-7 or -8 for all other animals) (Figure 3A). Fluctuations in clonal
frequencies were higher early after transplant (29 months)—
when the cluster-1 and -2 clones were the primary source of
blood repopulation—than at later time points (Figure S3B).
Most of the cluster-1 and -2 clones lasted for only months
whereas the clones that emerged later expanded and decayed
over years. These results indicate that repopulation occurs inCell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc. 475
Table 1. Summary of Vector Integration Site Sequence Analysis
Animal ID Infused CD34+ HSPCs (Marking) Cell Types Months Uniq. VI QVI (LT-QVI) Genom. Sites
95E132a 36 3 106 (20%; 7 3 106 GFP+) serial PBC (12) 4–145 803 492 (233) 726
CD4,CD8,CD20,CD14,CD18,CD34 116–117 399 259 (259) 365
total – 846 517 (259) 759
2RC003a,b 30 3 106 (30%; 9 3 106 GFP+) serial grans (9) 3–103 679 475 (229) 562
serial PBMC (9) 3–103 607 425 (210) 508
CD4,CD8,CD20,CD14,CD18,CD34 70–71 360 279 (279) 282
total – 938 614 (279) 737
RQ5427c 160 3 106 (7%; 11 3 106 GFP+) serial grans (9) 2–67 932 694 (349) 716
serial PBMC (10) 2–67 1,074 808 (385) 862
CD4,CD8,CD20,CD14,CD18,CD34 63–64 632 477 (477) 533
total – 1,527 1,120 (477) 1,147
RQ3570c 160 3 106 (18%; 29 3 106 GFP+) serial grans (6) 2–38 2,213 1,809 (913) 1,754
serial PBMC (7) 2–38 3,965 3,295 (1,306) 3,470
CD4,CD8,CD20,CD14,CD18,CD34 36–37 2,664 2,095 (2,095) 2,257
total – 5,758 4,586 (2,095) 4,817
HSPC, hematopoietic stem cell and progenitor cell; EGFP, enhanced green fluorescent protein; QVI, quantifiable vector integrant; LT-QVI, long-term
QVI; Genom. Sites, unambiguous genomic integration sites; PBC, total peripheral blood cells; grans, granulocytes; PBMC, peripheral blood mononu-
clear cells.
aHuman immunodeficient virus (HIV)-based, self-inactivating lentivirus vectors (SIN-HIV vectors) expressing EGFP were used to transduce the CD34+
cells prior to transplant (An et al., 2001; Sander et al., 2006).
bSIN-HIV vectors expressing the mutant viral herpes simplex virus-1 thymidine kinase (HSV1-sr39tk) gene were also used for animal 2RC003 for
position emission tomography (Sander et al., 2006).
cSimian immunodeficient virus (SIV)-based lentivirus vectors expressing both EGFP and shRNA against the HIV-1 coreceptor, C-C chemokine recep-
tor type 5 (CCR5), were used to transduce the CD34+ cells prior to transplant (An et al., 2007).
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about 1 year where clones rapidly appear and disappear and (2)
a long-term phase where more stable clones gradually emerged
and predominated the HSPC repopulation. Furthermore, even
the most stable clones appear to have a finite life span. Sequen-
tial declines of hundreds of clones are compensated for by
expansion of others, maintaining a relatively stable level of
marked cells over the ensuing years in each animal (Figure S3C).
Segregation of Long-Term and Short-Term
Repopulating Clones
Clones persisting for many years likely represent repopulation
by the progeny of HSCs. To specifically study the long-term
repopulating clones, we segregated QVI clones that were de-
tected near the experimental end point (long-term QVIs [LT-
QVIs], hereafter) in mature blood lineages (at 36, 64, 70, or
116 months from animals RQ3570, RQ5427, 2RC003, and
95E132, respectively) and in mPB CD34+ HSPCs isolated within
1 month of the mature lineage isolation (see Figure S4 and
Table 1). Of all identified QVI clones, about half (42%–50%)
were LT-QVIs, which indicates that approximately 0.01%
(0.008%–0.017% in each animal) of vector-marked CD34+
HSPCs transplanted into each animal were capable of long-
term repopulation above the detection level (see Supplemental
Experimental Procedures for details). The remainder (50%–
58%) were defined as short-term QVI clones (ST-QVIs). Most
LT-QVIs were undetectable or infrequent at 2–4 months post-
transplant, but beginning around 7–13 months posttransplant
they became the primary source of repopulating cells, contrib-476 Cell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc.uting to >80% of the total repopulation (Figure 3B). ST-QVIs pri-
marily occurred very early after transplant (within 2–4 months)
and dropped in frequency after the first year before the LT-
QVIs dominated. About half of detected clones were ST-QVIs,
but it is likely that there were a greater number of short-term
clones repopulating during this period that were undetected in
the analysis because of the limited blood sampling and analysis
time points. Thus, the ST-QVI clones possibly represent progeny
of hematopoietic progenitor cells that provided a rapid reconsti-
tution of hematopoiesis within the first year after transplant,
whereas LT-QVI clones likely represent HSCs that arose more
gradually and provided a longer lasting hematopoiesis.
LineageDisparate Subtypes of Long-TermRepopulating
Clones
We determined the lineage output of LT-QVI clones by fraction-
ating cells near the experimental end point into subpopulations
of myeloid (CD14+ and CD18+) and lymphoid (CD4+, CD8+,
and CD20+) cells. Individual LT-QVIs showed highly variable
detection frequencies in different cell types. To obtain reliable
patterns of clonal lineage potentials, LT-QVIs with an average
detection frequency of <0.0002 (average of myeloid cells
[CD14+ and CD18+], T cells [CD4+ and CD8+], and B cells
[CD20+]) were excluded from the analysis. The results revealed
three clearly distinguishable subtypes among the LT-QVIs that
differed in the proportion of lineage output to myeloid or
lymphoid cells (Figures 4A–4D and Figures S5A and S5B).
Myeloid-biased (My-bi), lymphoid-biased (Ly-bi), and balanced
(Bal) LT-QVIs were defined based on the myeloid (GM) and
Figure 2. Polyclonal Repopulation with Highly Variable Detection Frequencies among Clones
(A) The total number of unique vector integrants recovered in each animal (Uniq.VI [y axis] at all time points and for all cell types [see Table 1]) showed a linear
correlation with the total number of EGFP+ cells transplanted at the beginning of the experiment (x axis).
(B) The stacked area charts show the average detection frequencies of individual QVI clones in serial peripheral blood analysis, with the most prevalent QVI clone
located at the bottom. Total peripheral blood cells (PBCs) in animal 95E132 and both granulocytes (grans) and peripheral blood mononuclear cells (PBMCs) in
animals 2RC003, RQ5427, and RQ3570 are shown. The left vertical axis shows the cumulative contribution to overall repopulation by individual QVI clones. The
total number of QVI clones recovered in each animal appears beside a black arrow at the right of each chart. A large number (43%–71%) of QVI clones (denoted
by blue arrows) were detected at an extremely low average frequency of <0.0002, contributing to <7% of total blood repopulation over the entire course of
observation, except in animal RQ3570, where the contribution was <23%. By contrast, the 5% most frequently detected clones (denoted by red arrows)
contributed to an average of 49%–72% of total blood repopulation, depending on the animal and cell type. The mean and standard deviation (±STDEV) of QVIs
are noted at the bottom of each chart.
See Figures S1 and S2 for more details.
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respectively. These showed a high quality of separation for all
data sets (jZsummary.qualj > 10 using the WGCNA R package;
Langfelder and Horvath, 2008), except within animal 2RC003,
which had the two smallest clusters (with only 30 and 38 clones)
that did not achieve significance. In animals 95E132, RQ5427,
and RQ3570, the proportions of the My-bi, Bal, and Ly-bi clones
among the analyzed LT-QVIs were 25%31%, 23%33%, and
40%46%, respectively. In animal 2RC003, the My-bi propor-
tion was much greater (59%) than the others (18% and 23%
for Bal and Ly-bi, respectively), possibly because it was affected
by ganciclovir IV treatment at 23 months posttransplant. These
results provide a demonstration of highly heterogeneous lineage
output behaviors of long-term polyclonal repopulation in
primates.
Dynamics of My-bi, Ly-bi, and Bal Clone Repopulation
over Time
We observed that LT-QVIs became the dominant source of
hematopoietic reconstitution after rapid but transient reconstitu-
tion by a large number of ST-QVIs that declined primarily within
the first year (see Figure 3B). Here, we tracked the clones consti-
tuting three LT-QVI subtypes over time to understand how these
subtype clones contributed to long-term hematopoietic recon-
stitution. Interestingly, a small number of Bal type LT-QVI clones,
constituting only 4%–10% of total recovered QVIs, expanded
extensively during the first 1020 months and, after which
time, became the predominant source of long-term hematopoi-
etic reconstitution, ultimately contributing up to 71% (95E132),42%–52% (2RC003), 61%67% (RQ5427), and 25%–32%
(RQ3570) of total QVI repopulation (Figure 4E). The My-bi
LT-QVIs, constituting 6%–16% of total QVIs, also increased
gradually but maintained relatively lower levels than the Bal
type. In contrast to the My-bi and Bal clones, which increased
consistently over time, the Ly-bi LT-QVIs (6.2%–12.8% of total
QVIs) expanded for the first 1020 months and then gradually
declined. The greatest proportion of repopulation is ultimately
contributed by the Bal type clones, which contribute relatively
equally to myeloid and lymphoid repopulation.
We further examined the utilization of these clones over time
in blood cells fractionated for grans and PBMCs. Serial analysis
of fractionated grans and PBMCs in animals 2RC003, RQ5427,
and RQ3570 showed that the lineage-biased or -balanced
patterns of these clones started to be apparent at about
10 months posttransplant and sustained until the end point (Fig-
ure 4E and see Figure S6A for 10 most frequent clones).
Correlation of Clonal Behavior with Cluster Analysis
Through clonal tracking analysis we were able to define four
functionally distinct repopulating subpopulations arising from
the transplanted CD34+ HSPC pool, including short-term repo-
pulating clones and three subtypes (My-bi, Bal, and Ly-bi) of
long-term repopulating clones. We also determined their relative
contributions to hematopoietic reconstitution over time (see Fig-
ure 5A for a summary). In order to investigate the more detailed
dynamics of the clones constituting these subgroups, they were
compared with the kinetics clusters defined in Figure 3A. As
expected, the ST-QVIs were highly enriched in cluster-1,Cell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc. 477
Figure 3. Repopulation Kinetics of HSPC Clones
(A) Sequential expansions of HSPC clones over time. Major clonal kinetics patterns in serial PBCs (in animal 95E132) and PBMCs and grans (in animals 2RC003,
RQ5427, and RQ3570) were derived using average linkage hierarchical clustering based on clonal frequency profiles over time. The relative frequencies of QVI
clones at different time points (shown in months at the top of each chart) appear in a white-black-yellow color scheme, with white denoting zero frequency and
yellow the highest frequency (see the numbers at the bottom of each chart). QVIs were grouped into 5–8 clusters (denoted by different colored arrows), depending
on animal and cell type, using theWGCNApackage (Langfelder andHorvath, 2008). All clusters were clearly separable, with a significance level (jZsummary.qualj)
> 10 (Langfelder andHorvath, 2008), except for cluster-1 in the 2RC003 PBMCdata set (only nineQVI clones). Results showed that different groups of QVI clones,
beginning with cluster-1, expanded sequentially over time. See Figure S3 for more details.
(B) Repopulation of long-term and short-term QVI Clones. Long-term QVI clones (LT-QVIs) and short-term QVI clones (ST-QVIs) were segregated based on the
presence of these clones in blood lineages isolated at 116–117 months (95E132), 70–71 months (2RC003), 63–64 months (RQ5427), or 36–37 months (RQ3570)
posttransplant. The relative contributions (y axis) of LT-QVIs (orange) and ST-QVIs (black) in serial PBCs (95E132) or grans/PBMCs (2RC003, RQ5427, and
RQ3570) are shown over time.
See Figure S4 for more details.
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after, except serial PBMCs in 2RC003 (Figure 5B). Conversely,
LT-QVIs were found primarily in clusters appearing later. As
expected from the increasing patterns over time, My-bi and
Bal type QVIs were enriched in the clusters that appeared the
latest (cluster-7 or -8 for 95E132, 2RC003, and RQ5427, and
cluster-5 or -6 for RQ3570), whereas Ly-bi clones did not show
such a pattern (Figure 5B). The results indicate that within each
given lineage subtype, individual clones rise, peak, and fall at
different times.478 Cell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc.The Relative Proportions of My-bi, Bal, and Ly-bi Clones
in the CD34+ HSPC Pool
Because some mature cells persist for years, the relative propor-
tions of My-bi, Bal, and Ly-bi clones assessed in mature cells
may not reflect those in stem cells or progenitors. The relative fre-
quencies of these long-term QVI clones in mature lineages were
compared near the experimental end points for each animal with
those in the underlying HSPC pool (37, 63, 71, or 117 months).
mPB CD34+ HSPCs were collected within 1 month of the blood
used for lineage fractionation (Table 1). For most animals the
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Long-Term Clonal Tracking of Primate HSPCsmajorityof theBal andMy-bi cloneswerepresent in theHSPCpool
(57%–96% of the Bal type and 38%–80% of My-bi clones were
shared with the HSPC pool) (Figure 5C and also see Figures 4A–
4D). In contrast, only 17%–50% of Ly-bi clones were common to
the HSPC pool. When My-bi, Bal, and Ly-bi LT-QVI clones that
were present in the CD34+ HSPCs were tracked over time, we
found that the unique lineage-biased or -balanced patterns of
these clones became apparent at around 1 year posttransplant
and were maintained over time (Figure S6B). The majority of Ly-
bi clones occurred in both grans and PBMCs at earlier time points
but persisted primarily in PBMCs until the end point. We also
observed that the clonal composition between the HSPCs and
the lymphoid cells (CD4+, CD8+, and CD20+ cells) was generally
less correlated than the clonal compositions between the HSPCs
andCD18+grans (Figure5D), as isexpectedbecause the relatively
short life span of grans would reflect the immediate output of pre-
cursor cell differentiation. These results indicate that the long-term
HSPC population is relatively enriched for the Bal and the My-bi
clones. A smaller proportion of Ly-bi LT-QVIs were maintained
above the detection level in the long-term engrafted HSPC pool.
This result may reflect the longer life span of lymphoid cells and
consequently a decreased requirement for Ly-bi clones with age.
VIS Analysis Indicates Benign Integration Bias without
Selection for Any Particular Cell Type
As seen in previous gene-therapy clinical studies using murine
leukemia virus (MLV) vectors, insertional mutagenesis may
cause aberrant clonal proliferation or skewed differentiation.
While low genotoxic effects of lentivirus vectors have been
demonstrated in recent studies by VIS analysis for up to 2 years
in humans (Aiuti et al., 2013; Biffi et al., 2013; Cartier et al., 2009;
Cavazzana-Calvo et al., 2010), careful monitoring of the long-
term effects by lentivirus vectors is required because gene-
modified HSCs will be maintained for a lifetime. Genomic VIS
patterns of repopulating cells in our test animals largely reflect
those of freshly transduced CD34+ HSPCs (acute infection) (Fig-
ure S7A). We also found several local VIS hot spots common in
all test animals but undetected in acute infection of mPB
CD34+ cells (Figure 6). These hot spots were characterized using
a Bayesian change-point (BCP) model that defines VIS hot spots
relatively independently of data set size (Presson et al., 2011).
Lentivirus vectors showed distinctive VIS hot spot patterns that
differed from oncogenic MLV vectors. Clinical gene-therapy
studies with MLV vectors have revealed hot spots consisting of
densely clustered VISs in a small genomic region, typically
near the transcription start site of a gene, that often differed
across individuals (Deichmann et al., 2007; Presson et al.,
2011; Wang et al., 2010). In contrast, the lentivirus vector hot
spots in our test animals consisted of VISs spread across multi-
genic, megabase-scale regions (Figure S7B). These hot spots
were conserved in all time points and cell types without any
notable changes in size or intensity (Figure S7C). Similar hot
spot patterns were also observed at homologous regions in
humans (Presson et al., 2011) and in mice (Biffi et al., 2011).
Through analysis of PBMC, grans, and PBC data sets, we found
that VIS hot spots were not correlated with highly expanded
clones (data not shown). When the genes hosting VISs in
My-bi, Bal, Ly-bi, or ST-QVI data sets were compared with
each other, no notable functional gene group was associatedwith any specific cell type (Figures S7D and S7E). Thus, these
results demonstrate an apparently benign integration bias not
associated with any particular HSC subtype.
DISCUSSION
To date, our understanding of the primate hematopoietic system
lags far behind the level desired for current and future use of
HSPC-based therapies (Cavazzana-Calvo et al., 2011; Copley
et al., 2012; Doulatov et al., 2012). Despite the significant
advances in HSPC-based therapies, the phenotypic properties
of primate HSCs during hematopoietic reconstitution after trans-
plant remain unclear. We provide here a detailed system-level
descriptionof thedecade-longpropertiesofa largenumberofhet-
erogeneousclones followingnonhumanprimateCD34+cell trans-
plant andaddresshow long-termandstablehematopoietic recon-
stitution over 4 to 12 years was achieved through the combined
contributions of thousands of clones. Remarkably, despite waves
of HSPC utilization lasting for periods of months or years, total
marking remains relatively constant for over10years.And, despite
lineage-disparate behaviors of HSPCs, normal repopulation of
blood cell lineages is maintained, initially through the contribution
of short-livedHSPC clones, but eventually themajority of repopu-
lation is determined by a few stable clones having a relatively
balancedmultilineage output. The results suggest tremendous di-
versity as well as intricate control of HSPC repopulation.
Classically, HSCs were thought to be largely biologically
homogeneous in regards to self-renewal and differentiation
potential. Recent single-cell transplant studies in mice intro-
duced new complexity into the regulation of the hematopoietic
system, showing significant heterogeneity in longevity, self-
renewal, and differentiation potentials among the most primitive
HSCs (Copley et al., 2012;Muller-Sieburg et al., 2012). Unlike the
murine transplant studies using purified HSCs, primate trans-
plant occurs through the combined and competitive repopula-
tion by a vastly greater number of HSPC clones over a longer
period of time. The majority of repopulating clones in our test
animals showed a kinetic pattern indicating finite life spans of
engrafted HSPCs. These clones made their peak contribution
at different time points and could be grouped into several clus-
ters based on their repopulation kinetics, showing sequential
expansions of different groups of clones over months for the
earliest clones and over years for those clones appearing later
after repopulation (Figure 3A). Of the clones detected, approxi-
mately equal numbers are long-term (LT-QVI) and short-term
(ST-QVI) clones. Although the assay end point given to each
animal to distinguish long-term and short-term clones ranged
from 3 to 10 years, this variation in end points did not significantly
affect our findings regarding the relative frequencies of these two
populations insofar as the clonal kinetics in all animals became
more stable after 1–2 years. We estimated approximately
0.01% of transplanted CD34+ cells (1 in 1–2 million mobilized
PBMCs) were capable of long-term repopulation above the
detection limit. Our estimate is comparable to an estimate of
the human HSC frequency (1 in 1–6 million cells in cord blood,
adult bone marrow, or mPB) by limiting dilution analysis using
immunodeficient mouse xenotransplant models (Doulatov
et al., 2012; Wang et al., 1997). An exquisite balance exists be-
tween the expansions of newly arising clones and the declinesCell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc. 479
(legend on next page)
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of transplanted clones in the blood over years. The clones de-
tected early after transplant (within the first 7 to 9 months)
were of large number, were mostly low-frequency, and persisted
transiently, whereas the clones detected later were kinetically
more stable, expanding slowly and often intensively over years
before subsiding and being replaced by new groups of clones.
This sequential pattern of polyclonal repopulation suggests
that stable long-term hematopoietic reconstitution is achieved
by expansions of HSPCs with different longevities. Differences
in the life span of HSCs have also been observed in mice where
transplantation of single HSCs exhibited wide differences in
longevity (Benveniste et al., 2010; Sieburg et al., 2011). We hy-
pothesize that the large number of early clones represent more
differentiated progenitors that repopulate into the blood rela-
tively quickly, making only brief contributions but ensuring
adequate hematopoiesis and consequently survival of the host
during this critical early period aftermyeloablation.More detailed
insights into the clonal behaviors during this period are provided
in a related nonhuman primate study by Wu et al. (2014),
published in this issue of Cell Stem Cell, showing transient repo-
pulation of unilineage clones occurring primarily at 1–2 months
followed by more stable repopulation of multilineages clones.
Our long-term analysis data show that those HSCs at a more
primitive stage take more time to make their peak contribution
to the blood and persist for much longer but still finite times.
Many clones remain undetected until many years after transplant
before arising to replace decaying clones. The replacement of
subsiding clones with new groups of HSCs in order to maintain
a constant level of marked hematopoietic output further sug-
gests that there exist host environmental cues that instruct
new clones to emerge as old clones decay.
Long-term clones exhibit highly variable lineage output. Many
clones were relatively balanced in terms of their contributions to
myeloid and lymphoid lineages (balanced subtype), but others
showed a biased differentiation pattern favoring either myeloid
output (My-bi) or lymphoid output (Ly-bi). Among the Ly-bi
clones, some were highly skewed toward either T or B cells.
Over the long term, a small number of the Bal subtype clones
(4%–10%) expanded extensively and predominantly contributed
to the total blood repopulation (25%–71%). While the detailed
lineage cell-sorting fractionations were performed at a single
late time point, we demonstrated in three animals that within
blood fractionated at multiple time points for grans, representing
myeloid cells, and PBMCs, representing 80%–90% lymphoid
cells, those Bal subtype clones predominated after about 1–2
years (see Figure 4E). The dominance of the Bal subtype wasFigure 4. Functional Subtypes of Long-Term Repopulating Clones
(A–D) Myeloid-biased (My-bi), balanced (Bal), and lymphoid-biased (Ly-bi) sub
(magenta), and Ly-bi (green) groups were determined based onmyeloid (GM) to ly
each subpanel (i), the frequency profiles of individual QVIs are shown in a white-bla
myeloid cells (GM: CD18+ and CD14+ cells) andmPB CD34+ cells near the end p
The range of clones detected in CD34+ cells is indicated by a red arrow. The num
diagrams show the lineage output potentials of each clone (indicated by the positio
clones (indicated by the size of the circles) in mature lineages (ii) are compared t
(E) The total contributions to blood repopulation by My-bi, Bal, and Ly-bi QVIs (up
(lower chart) are shown over time. Error bars indicate standard errors.
See Figures S5 and S6 for more details.also suggested in a recent murine study (Lu et al., 2011); how-
ever, this study was performed at only a single time point, thus
lacking longitudinal HSC behavior data. Thus, our results provide
evidence for the coexistence of phenotypically lineage disparate
clones contributing to hematopoiesis in primates. The domi-
nance of Bal type HSC clones is to be teleologically expected
in order to maintain uniform blood lineage production over time.
The Ly-bi and My-bi clones are present in each of the animals
over the duration of our study although they contribute less
than Bal clones to total repopulation. The analysis of these
clones in granulocyte and PBMC fractions suggests conser-
vation of these lineage properties over time, although more
detailed longitudinal cell fractionation will be required for confir-
mation. In murine studies, the clones restricted for myeloid
output (Ly-bi) correlate with short longevity: self-renewal activity
of this type of cell was exhausted within 6–7 months (Dykstra
et al., 2007). In our studies, Ly-bi clones were maintained over
the long term; however, each animal showed a notable decrease
in the number of Ly-bi clones within the CD34+ progenitor cell
population at the assay end point (3–10 years posttransplant),
suggesting potential quiescence or exhaustion of some previ-
ously activated Ly-bi progenitors. By contrast, balanced and
My-bi long-term clones were relatively well conserved in the
CD34+ cells (see Figures 4A–4D and Figure 5C). Since mature
lymphoid cells have a far greater life span than myeloid cells,
the reduced frequency of Ly-bi clones in CD34+ cells may reflect
a reduced requirement for Ly-bi HSCs over time. The role of the
lineage-biased clones is unknown, but it is interesting to specu-
late that they may be instructed by environmental factors to
contribute to certain blood lineages in times of particular need
or stress.
Previous clinical trials with gamma-retroviral vectors have
been associated with cancers (Hacein-Bey-Abina et al., 2010;
Nienhuis et al., 2006; Stein et al., 2010); hence, the safety and
efficacy of therapeutic vectors have been a concern for future
HSPC-based genetic therapies. Despite safer clonal repopula-
tion patterns found in recent human gene therapy studies with
lentiviral vectors followed for 1.5–2 years by VIS analysis (Aiuti
et al., 2013; Biffi et al., 2013; Cartier et al., 2009; Cavazzana-
Calvo et al., 2010), potentially life-long persistence of engineered
stem cells warrants more careful monitoring of repopulating
clones for a much longer period. We demonstrate safe and sta-
ble hematopoietic reconstitution in nonhuman primates over
4–12 years (equivalent to 10–30 years in humans, based on the
average life span of the two species) without evidence of clones
with obvious aberrant behavior. Gene modification of HSPCs
with an shRNA directed to CCR5, an essential coreceptor fortypes among the LT-QVIs are shown for each animal. The My-bi (blue), Bal
mphoid (BT) cell ratios ofR3:1, between 3:1 and 1:3, and%1:3, respectively. In
ck-yellow color scheme for lymphoid cells (BT: CD4+, CD8+, and CD20+ cells),
oint and serial PBC(95E132) or grans/PBMCs (2RC003, RQ5427, and RQ3570).
bers of QVI clones appear in parentheses. In subpanels (ii) and (iii), the ternary
ns of the circles relative to the points of the triangle). The relative frequencies of
o those of identical clones in mPB CD34+ cells (iii).
per chart) and the average contributions by individual QVIs within each group
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Figure 5. Summary Diagrams Showing the Relative Proportions of HSPC Subpopulations and Their Contributions to Blood Repopulation
over Time
(A) Summary diagrams. (Ai) shows the relative proportions of long-term repopulating cells within the transplanted CD34+ cell pool. (Aii) shows the contributions of
short-term clones (ST-Clones) and the three subtypes of long-term clones over time.
(B) These charts show variable repopulation kinetics among the clones within each subpopulation. The numbers of My-bi, Bal, Ly-bi, and ST-QVI clones in the
various kinetics clusters are indicated by bar graphs. The clusters and color codes for each cluster are the same as those in Figure 3A.
(C) The bar graphs show the proportions of My-bi, Bal, and Ly-bi clones present in the CD34+ HSPC pool near the end point (denoted by red bars) relative to the
total detected in the mature lineages (denoted by black bars) (see Figure 4Ai–4Di) for individual clones in mature lineages and CD34+ cells). The long-term HSPC
population is relatively enriched for the Bal and the My-bi clones.
(D) Comparison of clonal compositions across cell types. The relative frequencies of individual clones are compared between cell types. The Pearson correlations
coefficient value (r) is indicated by a rainbow color scheme.
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Long-Term Clonal Tracking of Primate HSPCsR5-tropic strains of HIV-1 (An et al., 2007), and targeting the
same region of CCR5 as a candidate anti-HIV gene therapeutic
for human clinical trials (http://www.clinicaltrials.gov; protocol
NCT01734850) showed no notable effects on HSPC longevity482 Cell Stem Cell 14, 473–485, April 3, 2014 ª2014 Elsevier Inc.or lineage-output behaviors. Thus, our long-term analysis can
serve as a frame of reference for monitoring the safe use of
HSPCs and lentiviral delivery in the clinic, including HIV gene
therapy and other therapies using HSPCs.
Figure 6. VIS Bias Conserved Across Animals and Functional Subgroups
(A and B) Genomic VIS hot spots in four test animals are shown in (A) in comparison with those of published (pub) and freshly infected naive CD34+ cells (acute).
Hot spots in My-bi, Ly-bi, Bal, and ST-QVIs (four animals combined) are shown in (B). Each row shows the complete VIS pattern for one data set, where data set
names are indicated on the y axis, and the x axis gives the genomic location of the VIS in Mb units. Vertical black bars indicate chromosomal boundaries. Color
definitions were assigned for each data set independently, based on relative VIS density. Hot spot regions are colored in red. One of the strongest hot spots was
located at chromosome (chr) 4 (29.9434.01 Mb) hosting about 4.22% of the total VIS with a density of about 69 VIS per Mb. The second major hot spot was
defined as a 4.99 Mb region at rhesus chr14 (5.9810.97 Mb) containing 5.54% of VIS at a density of 73 VIS/Mb. Hot spots among subtypes were significantly
correlated, with overlap ranging between 29%79%among subtypes and overlap p values (based on a Fisher’s exact test for hot bin overlap) ranging from 1.73
107 to 3.3 3 1022. See Table S3 and Figure S7 for more details.
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Animal Care and Peripheral Blood Cell Isolation
Four rhesus macaques were maintained in accordance with federal guidelines
and the policies of the Veterinary Research Program of the National Institutes
of Health according to the protocols approved by the Animal Care and Use
Committee of the National Heart, Lung, and Blood Institute. Procedures for
peripheral blood cell isolation can be found in the Supplemental Information.
VIS Analysis
VISs in repopulating cell samples were analyzed by TaqaI-mediated, bidirec-
tional VIS sequencing and bioinformatics analysis, as described previously
(Kim et al., 2010) with modifications for animals 2RC003, RQ3570, and
RQ5427 (see Supplemental Information for details).
Kinetics Clusters
Major clonal kinetics patterns were derived using the WGCNA R package
v.1.20 (Langfelder and Horvath, 2008). Clusters were defined by using thresh-
olds that were specific to each data set, where each threshold was selected
to yield clusters with visually distinct kinetics profiles. The significance of
the clusters was quantified using the modulePreservation function in the
WGCNA package (Langfelder and Horvath, 2008) as described above (See
Supplemental Information for details).
Lineage Analysis
Analogous to previous studies (Dykstra et al., 2007; Lu et al., 2011), the relative
contributions of individual LT-QVIs toward grans/monocytes (GM: CD14 andCD18), T cells (CD4 andCD8), and B cells (CD20) were determined with ternary
plots and cluster analysis using the WGCNA R package v.1.20 (see Supple-
mental Information for details).
Genomic Vector Integration Site Hot spots
The BCP model (Presson et al., 2011) was used to define hot spots (see Sup-
plemental Experimental Procedures for details). The correlation of hot spots
among different HSPC subtypes was tested based on a Fisher’s exact test
for hot bin overlap (see Supplemental Information for details).
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures, seven figures, and five tables and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2013.12.012.
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